Acps november 15 2000
This presentation is the property of its rightful owner.
Sponsored Links
1 / 12

ACPS November 15, 2000 PowerPoint PPT Presentation


  • 39 Views
  • Uploaded on
  • Presentation posted in: General

ACPS November 15, 2000. 314.70 Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and Drug Administration. Regulatory Approach. CDER’s regulatory approach to post approval CMC changes is evolving

Download Presentation

ACPS November 15, 2000

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Acps november 15 2000

ACPSNovember 15, 2000

314.70 Update

Nancy B. Sager, Associate Director

Office of Pharmaceutical Science

Center for Drug Evaluation & Research

Food and Drug Administration


Regulatory approach

Regulatory Approach

CDER’s regulatory approach to post approval CMC changes is evolving

  • 21 CFR 314.70 (1985 rewrite)

  • SU/PACs (early 90’s to present)

  • FDAMA (1997)

  • Implementation of FDAMA §116 (now)

  • Next ?


21 cfr 314 70 supplements and other changes to an approved application 1985 rewrite

21 CFR 314.70:Supplements and Other Changes to an Approved Application (1985 rewrite)

  • “The applicant shall notify FDA about each change in each condition established in an approved application beyond variations provided for in the application”

  • Provides a general listing of changes with reporting mechanisms


Acps november 15 2000

Scale Up/Post Approval Change - Guidance Documents

  • Minor change

  • Moderate change

  • Major change

  • Application / Compendial Tests

  • In Vitro Dissolution / Release

  • In Vivo

  • Annual Report

  • Changes Being Effected Supplement

  • Prior Approval Supplement

Level of

Changes

Tests

Filing


Fda modernization act section 116 november 1997

FDA Modernization ActSection 116 (November 1997)

  • Recognized the importance of the SU/PAC approach

  • Amended the Food, Drug, and Cosmetic Act by adding Section 506A

  • Required revision of 314.70

  • Guidance was developed to document FDA’s current thinking on how to apply Section 506A


Fdama section 116

FDAMA Section 116

Reporting categories are based on the potential for the change to adversely affect the identity, strength, quality, purity, or potency of a product as they may relate to the safety or effectiveness of the drug product.


Fdama section 116 reporting categories

FDAMA Section 116:Reporting Categories

  • Substantial potential

    • Prior approval supplements

  • Moderate potential:

    • Supplement — changes being effected in 30 days (CBE-30)

    • Supplement — changes being effected (CBE-0)

  • Minimal potential

    • Annual reports


Fdama 116 implementation status

FDAMA 116 Implementation Status

  • Draft guidance published for public comment on June 28, 1999; comment period closed on Aug. 27, 1999; final guidance published Nov. 1999

    (30 comment letters, 1200 individual comments)

  • Proposed regulation published for public comment on June 28, 1999; comment period closed on Sept. 13, 1999

    (30 comment letters, 300 individual comments)


Changes to an approved nda or anda nov 1999 guidance

Changes to an Approved NDA or ANDA (Nov. 1999 guidance)

  • Modeled on SU/PACs

  • Recommends reporting categories only

  • Covers all dosage forms

  • No recommendations on specific information that should be developed by the applicant to assess the effect of the change


Fdama 116 implementation status1

FDAMA 116 Implementation Status

The November 1999 guidance on Changes to an Approved NDA or ANDA represents FDA’s current thinking on how it will apply the requirements of section 506A of the Act for NDA and ANDA products.


Fdama 116 implementation status cont d

FDAMA 116 Implementation Status(cont’d)

Until the final regulation for § 314.70 publishes, section 506A is the sole basis for FDA’s regulation of postapproval manufacturing changes for products approved in NDAs or ANDAs


Fdama 116 implementation status cont d1

FDAMA 116 Implementation Status(cont’d)

  • The final rule for § 314.70 has been drafted and is in the beginning stages of the clearance process (ETA = winter/spring)

  • The guidance on Changes to an Approved NDA or ANDA is being revised to conform to § 314.70 and will publish at the same time as the final rule.


  • Login